Meritain Eldorado policies

Search Meritain Eldorado's public medical, payment and drug policies by CPT or HCPCS code, keyword or policy number, with links to the payer's own documents. Links open the payer's own document; check its current version before relying on it.

91 policies name 96372, those listing the fewest codes first. A policy that names a code may also list it as excluded.

Meritain Eldorado policies
PolicyDetailsCodesSource
0882-Metreleptin (Myalept)0882 · Commercial1Original policy ↗
0933-Pegvaliase-pqpz (Palynziq)0933 · Commercial2Original policy ↗
1090-Zopapogene Imadenovec-drba (Papzimeos)1090 · Commercial2Original policy ↗
1096-Plozasiran (Redemplo)1096 · Commercial2Original policy ↗
0762-Repository Corticotropin Injection (Acthar Gel and Purified Cortrophin Gel)0762 · Commercial3Original policy ↗
0938-Ketamine for the Treatment of Depression and Other Selected Indications0938 · Commercial3Original policy ↗
1061-Collagenase Clostridium Histolyticum (Xiaflex)1061 · Commercial3Original policy ↗
0961-Givosiran (Givlaari)0961 · Commercial4Original policy ↗
0987-Cabotegravir and Rilpivirine (Cabenuva)0987 · Commercial4Original policy ↗
0963-Luspatercept-aamt (Reblozyl)0963 · Commercial5Original policy ↗
0983-Lumasiran (Oxlumo)0983 · Commercial6Original policy ↗
1015-Testosterone Enanthate Injection1015 · Commercial6Original policy ↗
0709-Nesiritide (Natrecor)0709 · Commercial7Original policy ↗
1014-Testosterone Cypionate Injections1014 · Commercial7Original policy ↗
0954-Romosozumab-aqqg (Evenity)0954 · Commercial8Original policy ↗
1088-Clesrovimab-cfor (Enflonsia)1088 · Commercial8Original policy ↗
Testosterone Undecanoate (Aveed) Injection0528 · Commercial8Original policy ↗
0768-Romiplostim (Nplate)0768 · Commercial9Original policy ↗
0974-Ado-trastuzumab emtansine (Kadcyla)0974 · Commercial9Original policy ↗
1027-Respiratory Syncytial Virus (RSV) Vaccines for Adult and Maternal Use1027 · Commercial9Original policy ↗
Burosumab-twza (Crysvita)0932 · Commercial9Original policy ↗
0949-Caplacizumab-yhdp (Cablivi)0949 · Commercial10Original policy ↗
1004-Inclisiran (Leqvio)1004 · Commercial11Original policy ↗
1038-Nirsevimab-alip (Beyfortus)1038 · Commercial11Original policy ↗
0901-Asfotase alfa (Strensiq)0901 · Commercial12Original policy ↗
1047-Nedosiran (Rivfloza)1047 · Commercial12Original policy ↗
0524-Zoledronic Acid0524 · Commercial13Original policy ↗
Progestins0510 · Commercial13Original policy ↗
0022-Calcitriol, Etelcalcetide, and Paricalcitol Injections0022 · Commercial14Original policy ↗
Hereditary Angioedema0782 · Commercial14Original policy ↗
0234-Chelation Therapy0234 · Commercial15Original policy ↗
0779-Plerixafor0779 · Commercial15Original policy ↗
1048-Mirikizumab-mrkz (Omvoh)1048 · Commercial15Original policy ↗
Gene-Based Therapy for Duchenne Muscular Dystrophy (DMD)0911 · Commercial17Original policy ↗
Thyrogen (Thyrotropin Alfa)0515 · Commercial17Original policy ↗
0748-Panitumumab (Vectibix)0748 · Commercial18Original policy ↗
Vitamin B-12 Therapy0536 · Commercial19Original policy ↗
0910-Extended-Release Buprenorphine Injectables0910 · Commercial20Original policy ↗
0675-Bortezomib Products0675 · Commercial23Original policy ↗
0939-Transthyretin-Mediated (ATTR) Amyloidosis0939 · Commercial25Original policy ↗
0804-Denosumab0804 · Commercial27Original policy ↗
1013-Spesolimab-sbzo (Spevigo)1013 · Commercial28Original policy ↗
1035-Rozanolixizumab-noli (Rystiggo)1035 · Commercial28Original policy ↗
Intravenous Iron Therapy0575 · Commercial28Original policy ↗
Trastuzumab Products0313 · Commercial28Original policy ↗
Gonadotropin-Releasing Hormone Analogs and Antagonists0501 · Commercial29Original policy ↗
Female Sexual Dysfunction (FSD)0574 · Commercial30Original policy ↗
Somatostatin Analogs0693 · Commercial31Original policy ↗
0195-Erythropoesis Stimulating Agents0195 · Commercial32Original policy ↗
0810-Gout0810 · Commercial34Original policy ↗

Back to Meritain Eldorado

Disclaimer

The information provided on this page is for general informational purposes only and does not constitute billing, coding, or reimbursement advice. Nothing on this page should be relied upon as a substitute for clinician assessment, professional billing guidance, or as a definitive statement of any payor's billing requirements or policies.

Payor agreements, fee schedules, and billing policies vary and are subject to change. Before submitting any claims related to maternity care services, including claims affected by the 2027 CPT code revisions, please consult the applicable payor agreements, coverage policies, and billing guidelines to confirm current requirements for their specific payor contracts.

Substrate makes no representation or warranty regarding the accuracy, completeness, or timeliness of the payor-specific information presented here. Providers are solely responsible for ensuring that all claims are submitted in accordance with applicable payor requirements, and Substrate assumes no liability for claim denials, underpayments, or other adverse outcomes arising from reliance on this information.